NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

阿茲海默症:全球臨床實驗趨勢

Alzheimer's Disease Global Clinical Trials Review, H1, 2020

出版商 GlobalData 商品編碼 222294
出版日期 內容資訊 英文 1130 Pages
訂單完成後即時交付
價格
阿茲海默症:全球臨床實驗趨勢 Alzheimer's Disease Global Clinical Trials Review, H1, 2020
出版日期: 2020年05月08日內容資訊: 英文 1130 Pages
簡介

本報告提供阿茲海默症治療藥相關臨床實驗最新趨勢相關分析,疾病、治療方法概要,及主要G7 (主要7個國家) 各國及E7 (新興7個國家) 的臨床實驗狀況,各地區、階段 (相)、階段的進展,有潛力的贊助商,各企業、研究機關的主要產品和臨床實驗的進展,有潛力的藥劑比較,臨床實驗現況、成果的最新資訊,今後的進展預測等資訊彙整,為您概述為以下內容。

本報告概要

本報告分析範圍

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區的主要5個國家的臨床實驗數量
    • 歐洲的主要5個國家的臨床實驗數量
    • 北美的主要國家的臨床實驗數量
    • 中東、非洲的主要5個國家的臨床實驗數量
    • 中南美的主要5個國家臨床實驗數量

在G7各國臨床實驗數量:中樞神經系統疾病治療藥臨床實驗的阿茲海默症的比率

在G7各國臨床實驗數量:各相 (各階段)

在G7各國臨床實驗數量:各進展狀況

在E7各國臨床實驗數量:中樞神經系統疾病治療藥臨床實驗的阿茲海默症的比率

在E7各國臨床實驗數量:各相 (各階段)

在E7各國臨床實驗數量:各進展狀況

各方面的臨床實驗數量

  • 進行中的臨床實驗:各相

臨床實驗數量:各進展狀況

臨床實驗的目標的達成情形

一定期間所採用的實驗對象

臨床實驗數量:贊助商的各類型

有潛力的贊助商

  • 參與阿茲海默症治療藥臨床實驗的主要企業

有潛力的藥劑

阿茲海默症治療藥:最新臨床實驗趨勢

臨床實驗的簡介:概要

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC6207CTIDB

GlobalData's clinical trial report, "Alzheimer's Disease Global Clinical Trials Review, H1, 2020" provides an overview of Alzheimer's Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Alzheimer's Disease Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Alzheimer's Disease
  • Mar 09, 2020: Study shows Nilvadipine slows early-stage Alzheimer's disease
  • Mar 05, 2020: AC Immune to present new data on neurodegenerative program ACI-35.030 at the Upcoming Advances in Alzheimer's and Parkinson's Therapies Focus Meeting
  • Mar 03, 2020: Alzheimer patients at Swedish clinics to be included in Phase 3 study of drug candidate BAN2401
  • Feb 27, 2020: Inflazome's Somalix demonstrates positive safety, tolerability and pharmacodynamic profile in its phase I study
  • Feb 26, 2020: ProMIS Neurosciences initiates natural history study of blood-based biomarkers in Alzheimer's Disease
  • Feb 20, 2020: Annovis issued patent for method of treating Parkinson's Disease and other lewy body diseases
  • Feb 14, 2020: Annovis Bio to continue DISCOVER Alzheimer's trial
  • Feb 12, 2020: Oligomerix presents preclinical data at TAU2020 Global Conference for small molecule inhibitor of tau self-association
  • Feb 11, 2020: Cassava Sciences announces Phase 2a study of PTI-125 published in the Journal of Prevention of Alzheimer's Disease (JPAD)
  • Feb 11, 2020: T3D Therapeutics begins enrollment in the PIONEER Phase 2 clinical trial of T3D-959 in patients with mild to moderate alzheimer's disease
  • Clinical Trial Profile Snapshots

Appendix

  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About GlobalData
  • Contact Us
  • Source

List of Tables

List of Tables

  • Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region, 2020*
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials In

List of Figures

List of Figures

  • Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region (%), 2020*
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2020*
  • Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2020*
  • Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2020*
  • Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase (%), 2020*
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2020*
  • Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
  • GlobalData Methodology